Literature DB >> 6842393

Characterization of binding of the Ca++ channel antagonist, [3H]nitrendipine, to guinea-pig ileal smooth muscle.

G T Bolger, P Gengo, R Klockowski, E Luchowski, H Siegel, R A Janis, A M Triggle, D J Triggle.   

Abstract

A chemically heterogeneous group of compounds, the Ca++ channel antagonists, which includes verapamil, diltiazem and nifedipine inhibits excitation-contraction coupling in smooth and cardiac muscle by blocking Ca+ entry at a specific class of Ca++ channels. The binding of the nifedipine analog, [3H]nitrendipine, to a microsomal fraction from guinea-pig longitudinal smooth muscle has been characterized. Specific binding was saturable, linear with protein concentration and reversible. The apparent equilibrium dissociation constant was 1.63 +/- 0.06 X 10(-10)M and the maximum site density was 1.13 +/- 0.03 pmol/mg of protein determined from Scatchard analysis of equilibrium binding at 25 degrees C. Inhibition of binding was specific and stereoselective for Ca++ channel antagonist drugs and was unaffected by a variety of receptor active ligands. Correlations between binding and inhibition of mechanical response to methylfurmethide- and K+-stimulation in a series of nifedipine analogs were determined. A 1:1 correlation was found for the K+ tonic response, but for the phasic component of the K+ response and for both components of the methylfurmethide response the antagonists were more active as inhibitors of [3H]nitrendipine binding than as inhibitors of mechanical response. [3H]Nitrendipine binding was sensitive to other Ca++ channel antagonists including verapamil, D-600, diltiazem, flunarizine, lidoflazine and bepridil. Interaction with these agents suggests, consistent with previous reports, that more than one binding site for Ca++ antagonists exists. A variety of inorganic divalent and trivalent cations (Mn++, Co++, Ni++, Pb++, UO2++, Zn++, Cd++, Cu++, Tm+++ and La+++) inhibit specific [3H]nitrendipine binding. The data suggest that [3H]nitrendipine binding in smooth muscle is to a site which mediates the pharmacologic response.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6842393

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  58 in total

Review 1.  The purification of ion channels from excitable cells.

Authors:  J A Talvenheimo
Journal:  J Membr Biol       Date:  1985       Impact factor: 1.843

Review 2.  The molecular pharmacology and structural features of calcium channels.

Authors:  D R Ferry; A Goll; M Rombusch; H Glossmann
Journal:  Br J Clin Pharmacol       Date:  1985       Impact factor: 4.335

3.  Identification of two calcium channel receptor sites for [3H]nitrendipine in mammalian cardiac and smooth muscle membrane.

Authors:  R B Rogart; A deBruyn Kops; V J Dzau
Journal:  Proc Natl Acad Sci U S A       Date:  1986-10       Impact factor: 11.205

4.  Impaired M3 and enhanced M2 muscarinic receptor contractile function in a streptozotocin model of mouse diabetic urinary bladder.

Authors:  K J Pak; R S Ostrom; M Matsui; F J Ehlert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-03-27       Impact factor: 3.000

5.  Profile of in vitro binding affinities of neuroleptics at different rat brain receptors: cluster analysis comparison with pharmacological and clinical profiles.

Authors:  R Testa; G Abbiati; R Ceserani; G Restelli; A Vanasia; D Barone; M Gobbi; T Mennini
Journal:  Pharm Res       Date:  1989-07       Impact factor: 4.200

6.  Modulation produced by nifedipine of the unitary Ba current of dispersed smooth muscle cells of the rabbit ileum.

Authors:  Y Inoue; Z L Xiong; K Kitamura; H Kuriyama
Journal:  Pflugers Arch       Date:  1989-09       Impact factor: 3.657

7.  Pharmacological properties of voltage-dependent calcium channels in functional microvessels isolated from rat brain.

Authors:  N Morel; T Godfraind
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-10       Impact factor: 3.000

8.  Interaction of calcium channel blockers with non-neuronal benzodiazepine binding sites.

Authors:  E H Cantor; A Kenessey; G Semenuk; S Spector
Journal:  Proc Natl Acad Sci U S A       Date:  1984-03       Impact factor: 11.205

9.  Calcium modulatory properties of 2,6-dibutylbenzylamine (B25) in rat isolated vas deferens, cardiac and smooth muscle preparations.

Authors:  R Pirisino; G Banchelli; G Ignesti; L Mantelli; R Matucci; L Raimondi; F Buffoni
Journal:  Br J Pharmacol       Date:  1993-08       Impact factor: 8.739

10.  Interactions between a "calcium channel agonist", Bay K 8644, and calcium antagonists differentiate calcium antagonist subgroups in K+-depolarized smooth muscle.

Authors:  M Spedding; C Berg
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-11       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.